IVP receives Nasdaq notice after bid-price noncompliance and reverse splits

Rhea-AI Filing Summary

Inspire Veterinary Partners, Inc. (IVP) has received a notice from Nasdaq stating that its common stock no longer meets the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The notice also explains that the company is not eligible for an automatic compliance period because it has completed reverse stock splits over the past one and two years with a cumulative ratio of 250 shares or more to one under Listing Rule 5810(c)(3)(A)(iv). Nasdaq has stated that IVP’s securities will be suspended from trading on the Nasdaq Capital Market at the opening of business on November 24, 2025, with a Form 25-NSE filed to remove the securities from listing and registration, unless the company appeals by November 20, 2025. IVP plans to request a hearing, which will temporarily halt the suspension or delisting process, but there is no assurance it will retain its Nasdaq listing.

Positive

• None.

Negative

• Nasdaq has initiated delisting proceedings for IVP’s common stock after a prolonged bid-price deficiency, with trading suspension and a Form 25-NSE pending absent a successful appeal.

Insights

Equity & Listing Standards Analyst

IVP faces potential Nasdaq delisting after failing the minimum bid rule.

Inspire Veterinary Partners (IVP) has fallen out of compliance with Nasdaq’s minimum bid price requirement based on 30 consecutive business days of trading below the required level under Listing Rule 5550(a)(2). Because the company has executed multiple reverse stock splits over the past one and two years with a cumulative ratio of at least 250-to-1, Listing Rule 5810(c)(3)(A)(iv) prevents it from receiving a standard grace period to cure the deficiency.

Nasdaq has indicated that IVP’s securities will be suspended from trading on the Nasdaq Capital Market at the open on November 24, 2025, and that a Form 25-NSE will be filed to remove the securities from listing and registration, unless the company appeals by November 20, 2025. IVP plans to request a hearing before a Nasdaq Hearings Panel, which will stay the suspension and delisting process while the hearing is pending.

The outcome now depends on the Panel’s decision and IVP’s ability to demonstrate a path back to compliance, and the company explicitly notes that there can be no assurance it will be granted continued listing or succeed in regaining and maintaining compliance.

false 0001939365 0001939365 2025-11-17 2025-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: November 17, 2025

INSPIRE VETERINARY PARTNERS, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-41792		85-4359258
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

780 Lynnhaven Parkway, Suite 400 Virginia Beach, VA		23452
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (757) 734-5464

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001		IVP		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 13, 2025, Inspire Veterinary Partners, Inc. (the “Company”) received a notice letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share, for the prior 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Further, the Notice stated that, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for any compliance period specified in Rule 5810(c)(3)(A) due to the fact that the Company has effected a reverse stock split over the prior one-year period and has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one.

The Notice stated that the Company’s securities will be suspended from trading on The Nasdaq Capital Market at the opening of business on November 24, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq, unless the Company requests an appeal of such determination to Nasdaq’s Hearings Panel (the “Panel”) by November 20, 2025. The Company intends to request a hearing before the prescribed date, which request will stay any further suspension or delisting action by Nasdaq pending the ultimate conclusion of the hearing process. There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq. 

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 17, 2025	INSPIRE VETERINARY PARTNERS, INC.
	By:	/s/ Kimball Carr
	Name:	Kimball Carr
	Title:	President and Chief Executive Officer

2

FAQ

Why did Inspire Veterinary Partners (IVP) receive a Nasdaq delisting notice?

Inspire Veterinary Partners received a Nasdaq notice because the closing bid price of its common stock was below the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for the prior 30 consecutive business days.

What role did reverse stock splits play in IVPs Nasdaq compliance issue?

Nasdaq stated that under Listing Rule 5810(c)(3)(A)(iv), IVP is not eligible for a compliance period because it has effected a reverse stock split in the past year and one or more reverse stock splits over the past two years with a cumulative ratio of 250 shares or more to one.

When could IVPs stock be suspended and delisted from Nasdaq?

Nasdaq indicated that IVPs securities will be suspended from trading on the Nasdaq Capital Market at the opening of business on November 24, 2025, and a Form 25-NSE will be filed to remove the securities from listing and registration, unless IVP appeals in time.

How is Inspire Veterinary Partners responding to the Nasdaq notice?

Inspire Veterinary Partners intends to request a hearing before Nasdaqs Hearings Panel by November 20, 2025, which will stay any further suspension or delisting action while the hearing process is ongoing.

Is there any guarantee that IVP will keep its Nasdaq listing?

No. The company explicitly states there can be no assurance that the Hearings Panel will grant continued listing or that it will be able to regain compliance and maintain its Nasdaq listing.

What is Form 25-NSE mentioned in relation to IVPs stock?

Form 25-NSE is the document that Nasdaq plans to file with the U.S. Securities and Exchange Commission to remove IVPs securities from listing and registration on the Nasdaq Capital Market if the delisting proceeds.